Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Newly Diagnosed Multiple Myeloma: full-pipeline trial registry
1 of 3 indexed Newly Diagnosed Multiple Myeloma trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Newly Diagnosed Multiple Myeloma: 3 US clinical trials tracked, 1 recruiting.
Newly Diagnosed Multiple Myeloma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Larysa Sanchez, running 1 of these trials.
Enrollment posture brief
Registry condition newly-diagnosed-multiple-myeloma
OPEN 1 | RECR 33% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Newly Diagnosed Multiple Myeloma lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Newly Diagnosed Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Newly Diagnosed Multiple Myeloma is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
GlaxoSmithKline
NCT06679101
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Larysa Sanchez
NCT04052880
Multiple Myeloma and Exercise
Abramson Cancer Center at Penn Medicine
NCT01809717
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Newly Diagnosed Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Newly Diagnosed Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Newly Diagnosed Multiple Myeloma page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Newly Diagnosed Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Larysa Sanchez sponsors the most Newly Diagnosed Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See Larysa Sanchez's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Newly Diagnosed Multiple Myeloma condition card totals 3 registered trials; most-linked intervention Daratumumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.